Trials / Completed
CompletedNCT03218501
A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 269 (actual)
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety and dose response of SK-1405 for the treatment of subjects with uremic pruritus receiving hemodialysis, during 2 weeks of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SK-1405 high dose | SK-1405 high dose is to be administered orally once daily for 2 weeks |
| DRUG | SK-1405 low dose | SK-1405 low dose is to be administered orally once daily for 2 weeks |
| DRUG | Placebo | Placebo is to be administered orally once daily for 2 weeks |
Timeline
- Start date
- 2017-08-28
- Primary completion
- 2018-05-25
- Completion
- 2018-05-25
- First posted
- 2017-07-14
- Last updated
- 2019-03-08
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03218501. Inclusion in this directory is not an endorsement.